A month after winning FDA approval for its first drug, privately held Prestwick Pharmaceuticals Inc. was acquired by Canadian drugmaker Biovail Corp. in a $100 million deal. (BioWorld Today)
The much-anticipated data from Amgen Inc.'s pivotal fracture study of denosumab in postmenopausal women demonstrated a significant reduction in vertebral fracture rate and relatively clean safety profile, ending a month and a half of speculation among investors since top-line data were released in late July. (BioWorld Today)
A day before the release of highly anticipated detailed risk-benefit data for osteoporosis drug denosumab, Amgen Inc. said it was divesting three marketed products to Swedish specialty pharma firm Biovitrum AB in exchange for $130 million up front, plus potential sales milestones and royalties down the road. (BioWorld Today)
